May 1, 2009
CONTACT: Gayle Lynn Falkenthal, APRFalcon Valley Group
619-997-2495 or email@example.com
GBK Cosmetic Laser Dermatology Part of Clinical Trials for New FDA Approved Botox® Competitor
“Dysport®” works faster and lasts longer
(San Diego) - America’s most popular cosmetic treatment now has some new competition. For the first time in 20 years, the Food and Drug Administration has approved a new wrinkle reducer that will provide an alternative to Botox®. It’s called Dysport® and like Botox® it can be used to minimize crow’s feet and forehead furrows.
The new drug has some exciting advantages. Dr. Mitchel Goldman, Medical Director of GBK Cosmetic Laser Dermatology, is one of the select cosmetic dermatologists nationwide who participated for the past four years in the U.S. clinical research trials of Dysport®.
“Dysport® has a faster onset than Botox®. Where it usually takes five to seven days for Botox® to take effect, the results from Dysport® usually take effect in one to three days. Better yet, Dysport’s® effects last about 25% longer than Botox®, an average of four months,” said Goldman. “From my experience, Dysport® produces excellent results and the patients love it.”
The U.S. distributors of Dysport®, Medicis Pharmaceutical Corporation, said it expects to make Dysport® available nationwide within the next two months.
“I hold myself and my practice at GBK Cosmetic Laser Dermatology to a very high standard,” said, Goldman. “I want to be able to offer consumer the latest scientific advancements in treatment, whether it’s new products like Dysport® or Latisse®, innovations in lasers, or other cutting-edge cosmetic therapy choices,” said Goldman. “There are more ways than ever for people to look and feel their best, safely and effectively.”
“Today, the good news is that we have additional treatment to improve our appearance,” said Goldman. “But no matter how new or exciting a treatment might be, consumers need to remember when choosing any cosmetic procedure to be sure and confer with a, board-certified dermatologist, plastic surgeon or cosmetic surgeon who has experience with these specific procedures. You need an experienced physician to determine which treatments are right for you personally.”
Almost 2.5 million Americans had Botox® injections last year for cosmetic purposes, according to the American Society for Aesthetic Plastic Surgery. It is the single most popular cosmetic procedure in the United States.
About Dr. Mitchel P. Goldman
Dr. Goldman is a double board certified dermatologist and cosmetic surgeon who is renowned for his pioneering research of multiple laser techniques and skin rejuvenation. Dr. Goldman is a Volunteer Clinical Professor of Dermatology/Medicine for University of California, San Diego, and has written 18 medical textbooks on cosmetic and laser surgery, several of which are considered definitive medical texts in their respective fields, as well as over 300 peer-reviewed medical publications. Dr. Goldman has been featured on The Today Show, 20/20, The Discovery Health Channel, Wealth TV, E!, Extra, and The Swan, and in top publications including The Wall Street Journal, TIME, New York Times, Prevention, Elle, O Magazine, Self, Marie Claire, Harper’s Bazaar, Allure, Glamour, InStyle, More and Good Housekeeping.
About GBK Cosmetic Laser Dermatology
GBK Cosmetic Laser Dermatology is San Diego County’s leading cosmetic dermatology practice, dedicated to combining major cosmetic breakthroughs of science and medicine with beauty and creativity to bring the ultimate in rejuvenation. World-renowned board certified dermatologist and cosmetic surgeon Dr. Mitchel P. Goldman and colleagues Dr. Kimberly Butterwick and Dr. Douglas Keel offers clients a combined 50 years of experience in a full range of procedures in its surgical suites, recognized by the Accreditation Association for Ambulatory Health Care for meeting its nationally recognized high standards, as well as cutting-edge cosmetic dermatology. GBK Cosmetic Laser Dermatology stays on the cutting edge of medical technology with its participation in groundbreaking research studies and ongoing education. For more information, please visit www.gbkderm.com